A Phase II Randomised Controlled Trial of Adjuvant Tumour-Infiltrating Lymphocytes for Pretreatment Epstein-Barr Virus DNA-selected High-Risk Nasopharyngeal Carcinoma Patients.
EUROPEAN JOURNAL OF CANCER(2023)
Key words
Adoptive immunotherapy,Tumour-infiltrating lymphocytes,Epstein-Barr Virus DNA,High-risk,Nasopharyngeal carcinoma
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined